Download PDF
Klin Monbl Augenheilkd 2020; 237(01): 90-94
DOI: 10.1055/a-0972-9747
Offene Korrespondenz
Georg Thieme Verlag KG Stuttgart · New York

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“

Safety, Efficacy and Protective Aspects of an Add-on Paracentesis during Intravitreal Injections
Michael Janusz Koss
1   Augenheilkunde, Augenzentrum Nymphenburger Höfe
,
Matthias Bolz
2   Augenklinik, Johannes-Kepler-Universität, Linz, Österreich
,
Albert J. Augustin
3   Augenklinik, Städtisches Klinikum Karlsruhe
,
Frank Koch
4   Augenklinik, Klinikum der Johann Wolfgang Goethe Universität, Frankfurt am Main
,
Peter Szurman
5   Augenklinik Sulzbach, Knappschaftsklinikum Saar GmbH, Sulzbach/Saar
,
Boris Stanzel
5   Augenklinik Sulzbach, Knappschaftsklinikum Saar GmbH, Sulzbach/Saar
,
Sascha Fauser
6   Zentrum für Augenheilkunde, Universität zu Köln
,
Stefan Mennel
7   Augenklinik, Klinikum Feldkirch, Österreich
,
Urs Vossmerbäumer
8   Augenklinik, Universitätsmedizin Mainz
,
Marc D. de Smet
9   Retina and Inflammation Unit, Clinique de Montchoisi, Lausanne, Schweiz
,
Fabian Höhn
10   Augenklinik, Marienhospital Osnabrück
,
Michael Küchle
11   Augenpraxisklinik Erlangen, Erlangen
,
Birgit Lorenz
12   Augenklinik, Justus-Liebig-Universität, Gießen
,
Mathias Lüke
13   Augenheilkunde am Rheincenter, Köln
,
Lyubomyr Lytvynchuk
12   Augenklinik, Justus-Liebig-Universität, Gießen
,
Carsten H. Meyer
14   Smartlook Augenärzte, Aarau, Schweiz
,
Christoph Paul
15   Augenklinik, Philipps-Universität, Marburg
,
Eduardo B. Rodrigues
16   Augenklinik, Saint Louis Universität, Saint Louis, MO, USA
,
Norbert Schrage
17   Augenklinik Köln-Merheim, Köln
,
Claus Zehetner
18   Universitätsklinik für Augenheilkunde und Optometrie, Innsbruck, Österreich
› Author Affiliations
Further Information

Publication History

eingereicht 21 October 2018

akzeptiert 08 July 2019

Publication Date:
26 November 2019 (online)

Also available at
    Permissions and Reprints

Corrected by:

Erratum: Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“Klin Monbl Augenheilkd 2020; 237(01): e1-e1
DOI: 10.1055/a-1185-0060

Intravitreale Injektionen und akute Nebenwirkungen

Die Parazentese ist ein über Jahrzehnte lang vertrautes Mittel, um einen erhöhten intraokularen Druck (IOD) unmittelbar, kostenarm und nahezu komplikationslos zu eliminieren. Mit der Zulassung von VEGF-Inhibitoren für die Behandlung der altersbedingten Makuladegeneration (AMD) im Jahr 2007 [1] und dem rapiden Anstieg an intravitrealen Injektionen hat die Bedeutung der Parazentese erneute Aufmerksamkeit erlangt. Fakt ist, dass es mit jeder Volumeneingabe in den Glaskörperraum unweigerlich zu einem IOD-Anstieg kommt, der im individuellen Einzelfall beträchtlich sein und zu akuten Sehbeschwerden und Schmerzen führen kann. Eine Parazentese ist in solchen Fällen zwingend erforderlich, um bleibende Schäden zu vermeiden.

Comment to this article:

Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen. Zum Beitrag von M. J. Koss et al. (Leserbrief)Klin Monbl Augenheilkd 2020; 237(06): 787-788
DOI: 10.1055/a-1141-3969

 

  • Literatur

  • 1 Rosenfeld PJ, Brown DM, Heier JS. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
    CrossrefPubMedGoogle Scholar
  • 2 Hollands H, Wong J, Bruen R. et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-811
    CrossrefPubMedGoogle Scholar
  • 3 Gismondi M, Salati C, Salvetat ML. et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18: 658-661 doi:10.1097/IJG.0b013e31819c4893
    CrossrefPubMedGoogle Scholar
  • 4 Meyer CH, Rodrigues EB, Aguni J. et al. Scleral incisions evaluated by with anterior segment optical coherence tomography. Am J Ophthalmol 2009; 148: 321 doi:10.1016/j.ajo.2009.04.014
    PubMedGoogle Scholar
  • 5 Rodrigues EB, Grumann jr. A, Penha FM. et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther 2011; 27: 197-203
    CrossrefPubMedGoogle Scholar
  • 6 Degenring RF, Sauder G. Vitreous prolapse and IOL dislocation during intravitreal injection of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1043-1044
    CrossrefPubMedGoogle Scholar
  • 7 Viestenz A, Küchle M, Behrens-Baumann W. Bulbusexplosion durch intravitreale Injektion. Klin Monatsbl Augenheilkd 2008; 225: 1087-1090
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Sharei V, Höhn F, Köhler T. et al. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010; 20: 174-179
    CrossrefPubMedGoogle Scholar
  • 9 Lorenz K, Zwiener I, Mirshahi A. Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1573-1577 doi:10.1007/s00417-010-1490-y
    CrossrefPubMedGoogle Scholar
  • 10 Ziemssen F, Eter N, Fauser S. et al. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ophthalmologe 2015; 112: 246-254 doi:10.1007/s00347-014-3217-7
    CrossrefPubMedGoogle Scholar
  • 11 Munk MR, Ceklic L, Ebneter A. et al. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 2016; 94: e757-e764 doi:10.1111/aos.13157
    CrossrefPubMedGoogle Scholar
  • 12 Horsley MB, Mandava N, Maycotte MA. et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2010; 150: 558-561.e1 doi:10.1016/j.ajo.2010.04.029
    CrossrefPubMedGoogle Scholar
  • 13 Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2013; 44: 460-464 doi:10.3928/23258160-20130909-07
    CrossrefPubMedGoogle Scholar
  • 14 Beck M, Munk MR, Ebneter A. et al. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol 2016; 167: 10-17 doi:10.1016/j.ajo.2016.04.003
    CrossrefPubMedGoogle Scholar
  • 15 Kopić A, Biuk D, Barać J. et al. Retinal nerve fiber layer thickness in glaucoma patients treated with multiple intravitreal anti-VEGF (bevacizumab) injections. Acta Clin Croat 2017; 56: 406-414 doi:10.20471/acc.2017.56.03.07
    PubMedGoogle Scholar
  • 16 Prager SG, Lammer J, Mitsch C. et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmol 2018; 96: e195-e200 doi:10.1111/aos.13520
    CrossrefPubMedGoogle Scholar
  • 17 Lanzl I, Kotliar K. [Can Anti-VEGF Injections Cause Glaucoma or Ocular Hypertension?]. Klin Monatsbl Augenheilkd 2017; 234: 191-193 doi:10.1055/s-0043-101819
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Meyer CH, Liu Z, Brinkmann C. et al. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe. Acta Ophthalmol 2012; 90: e165-e166 doi:10.1111/j.1755-3768.2010.02072.x
    CrossrefPubMedGoogle Scholar
  • 19 Gerding H, Timmermann M. Accuracy and precision of intravitreally injected ranibizumab doses: an experimental study. Klin Monatsbl Augenheilkd 2010; 227: 269-272
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Kotliar K, Maier M, Bauer S. et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85: 777-781
    CrossrefPubMedGoogle Scholar
  • 21 Knip MM, Välimäki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 2012; 90: 254-258 doi:10.1111/j.1755-3768.2010.01904.x
    CrossrefPubMedGoogle Scholar
  • 22 Van der Lelij A, Rothova A. Diagnostic anterior chamber paracentesis in uveitis: a safe procedure?. Br J Ophthalmol 1997; 81: 976-979
    CrossrefPubMedGoogle Scholar
  • 23 Carnahan MC, Platt LW. Serial paracenteses in the management of acute elevations of intraocular pressure. Ophthalmology 2002; 109: 1604-1606
    CrossrefPubMedGoogle Scholar
  • 24 Lam DS, Chua JK, Tham CC. et al. Efficacy and safety of immediate anterior chamber paracentesis in the treatment of acute primary angle-closure glaucoma: a pilot study. Ophthalmology 2002; 109: 64-70
    CrossrefPubMedGoogle Scholar
  • 25 Arnavielle S, Creuzot-Garcher C, Bron AM. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2007; 245: 345-350
    CrossrefPubMedGoogle Scholar
  • 26 Cheung CM, Durrani OM, Murray PI. The safety of anterior chamber paracentesis in patients with uveitis. Br J Ophthalmol 2004; 88: 582-583
    CrossrefPubMedGoogle Scholar
  • 27 Trivedi D, Denniston AK, Murray PI. Safety profile of anterior chamber paracentesis performed at the slit lamp. Clin Exp Ophthalmol 2011; 39: 725-728 doi:10.1111/j.1442-9071.2011.02565.x
    CrossrefPubMedGoogle Scholar
  • 28 Kitazawa K, Sotozono C, Koizumi N. et al. Safety of anterior chamber paracentesis using a 30-gauge needle integrated with a specially designed disposable pipette. Br J Ophthalmol 2017; 101: 548-550 doi:10.1136/bjophthalmol-2016-309650
    CrossrefPubMedGoogle Scholar
  • 29 Azuara-Blanco A, Katz LJ. Infectious keratitis in a paracentesis tract. Ophthalmic Surg Lasers 1997; 28: 332-333
    PubMedGoogle Scholar
  • 30 Helbig H, Noske W, Kleineidam M. et al. Bacterial endophthalmitis after anterior chamber paracentesis. Br J Ophthalmol 1995; 79: 866
    CrossrefPubMedGoogle Scholar
  • 31 Meyer CH, Rodrigues EB, Michels S. et al. Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 2010; 26: 491-495 doi:10.1089/jop.2010.0045
    CrossrefPubMedGoogle Scholar
  • 32 Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol 2014; 49: 261-266
    CrossrefPubMedGoogle Scholar
  • 33 Funk M, Karl D, Georgopoulos M. et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009; 116: 2393-2399 doi:10.1016/j.ophtha.2009.05.039
    CrossrefPubMedGoogle Scholar
  • 34 Muether PS, Hermann MM, Dröge K. et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 2013; 156: 989-993.e2 doi:10.1016/j.ajo.2013.06.020
    CrossrefPubMedGoogle Scholar
  • 35 dellʼOmo R, Cassetta M, dellʼOmo E. et al. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. Am J Ophthalmol 2012; 153: 155-161.e2
    CrossrefPubMedGoogle Scholar
  • 36 Rezar-Dreindl S, Eibenberger K, Pollreisz A. et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol 2017; 95: e119-e127 doi:10.1111/aos.13152
    CrossrefPubMedGoogle Scholar
  • 37 Garweg JG, Zandi S, Pfister IB. et al. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. PLoS One 2017; 12: e0182571
    CrossrefPubMedGoogle Scholar
  • 38 Ichiyama Y, Sawada T, Kakinoki M. et al. Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration. Ophthalmic Res 2014; 52: 234-238 doi:10.1159/000365253
    CrossrefPubMedGoogle Scholar
  • 39 Bach A, Filipowicz A, Gold AS. et al. Paracentesis following intravitreal drug injections in maintaining physiologic ocular perfusion pressure. Int J Ophthalmol 2017; 10: 1925-1927 doi:10.18240/ijo.2017.12.22
    PubMedGoogle Scholar
  • 40 Soheilian M, Karimi S, Montahae T. et al. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol 2017; 255: 1705-1712 doi:10.1007/s00417-017-3702-1
    CrossrefPubMedGoogle Scholar
  • 41 Enders P, Sitnilska V, Altay L. et al. Retinal nerve fiber loss in anti-VEGF therapy for age-related macular degeneration can be decreased by anterior chamber paracentesis. Ophthalmologica 2017; 237: 111-118 doi:10.1159/000457907
    CrossrefPubMedGoogle Scholar